Compare LWLG & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | SGP |
|---|---|---|
| Founded | 1991 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 846.4M | 968.0M |
| IPO Year | 2011 | 2026 |
| Metric | LWLG | SGP |
|---|---|---|
| Price | $5.22 | $27.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.00 |
| AVG Volume (30 Days) | ★ 2.5M | 64.3K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $236,855.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $2.84 | $17.06 |
| 52 Week High | $18.71 | $30.56 |
| Indicator | LWLG | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 57.95 |
| Support Level | $3.81 | $25.00 |
| Resistance Level | $5.65 | $27.53 |
| Average True Range (ATR) | 0.30 | 1.29 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 15.89 | 42.92 |
Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.